High-throughput sensing SRU Biosystems specializes in high-throughput, label-free sensing for rapid screening of interactions across cells, proteins, genomic, peptide, antibody, and small molecule libraries, indicating opportunities to position tools for large-scale pharmaceutical target screening and genomics/proteomics workflows.

BIND technology advantage The BIND technology provides high sensitivity and throughput in monitoring biological interactions, suggesting sales potential for customers requiring scalable, real-time interaction data in drug discovery and diagnostic development.

Targeted formats Product integration into microtiter plates, microarray slides, and microfluidic formats opens conversations with academic labs and CROs needing versatile platforms for screening and assay development across cell-based and biochemical targets.

Mid-sized pharma fit With revenue in the mid-single to mid-double digits and competitors of larger scale, SRU offers a nimble, cost-effective collaboration option for mid-sized pharma/biotech firms seeking high-throughput, label-free screening capabilities.

Expansion opportunities There is potential to expand into proteomics, clinical diagnostics, and genomics workflows, leveraging existing tech stack and platform formats to upsell integrated sensing solutions to researchers pursuing large-scale interaction mapping.